Catalys Pacific Phase III Select Fund, LP (Formerly known as Catalys Pacific Post-POC Fund, LP）
Date announced
May 15, 2025
Amount investedAmount of commitment
USD14 million
Fund summary
Invests in drug discovery startups from its existing fund portfolio that are developing drug candidates in Phase 3 clinical trials, and supports late-stage development through to new drug approval and subsequent commercialization.
Provides growth capital to mid- and later-stage startups and supports their development by introducing them to its domestic and international network. It aims to contribute to the diversity of domestic company management by leveraging a track record of investing in women entrepreneurs through existing fund.
Focuses on supporting the cutting-edge drug discovery technologies of academia, research institutes, pharmaceutical companies and other organizations from the startup stage. It primarily invests in Japanese drug discovery seeds to commercialize them. It leverages its overseas investment infrastructure and network to invest in early-stage global drug discovery startups.
Invests in large- and mid-sized listed companies in Japan and develops trusted relationships with the management teams of investee companies to support management initiatives aimed at long-term, sustainable growth and enhanced corporate value. As a major shareholder in investee companies, it seeks to encourage them to take healthy risks and invest in growth, adopting a sustainable approach to enhance their corporate value and improving their key performance metrics to foster the development of corporate activities of the large- and medium-sized Japanese companies that drive the Japanese economy, and to create a virtuous cycle for the broader Japanese economy.
Domestic investment and Innovation
Startup
Regional management resources
Business consolidation